Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on May 25, 2023. The filing serves as a Regulation FD disclosure regarding clinical trial progress for the Company's investigational drug candidate, RLY-4008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the completion of full dose escalation data collection for the ReFocus trial of RLY-4008. RLY-4008 is described as an investigational, potent, selective, and oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2).
Outlook and Management Commentary
- Upcoming Presentation: The Company plans to present the full dose escalation data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2023.
- Regulatory Status: The information provided in this Item 7.01 and the attached press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Verify the specific clinical data points and safety profile details in the attached press release (Exhibit 99.1) and the upcoming ASCO presentation.
- Confirm the timeline for the next phase of the ReFocus trial following the dose escalation completion.
- Review the Company's most recent quarterly or annual report (10-Q or 10-K) for current cash position and burn rate, as this 8-K does not contain financial data.